| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Takeda Pharmaceutical Co Ltd, Tobira Therapeutics Inc | AIDS Dementia Complex; Cholangitis, Sclerosing; Cognition Disorders; Coronavirus Disease 2019 (COVID-19); Diabetes Mellitus, Type 2; Hepatic Insufficiency; HIV Infections; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Prediabetic State | 詳細 |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | 詳細 |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | Acquired Immunodeficiency Syndrome; Colorectal Neoplasms; HIV Infections | 詳細 |
| Leronlimab | PA-14; PRO-140; HuPRO-140 | Phase 2 Clinical | Progenics Pharmaceuticals Inc | Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; HIV Infections; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 詳細 |
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Diabetic Nephropathies; Hyperplasia; Pancreatic Neoplasms | 詳細 |
| RAP-103 | RAP-160; RAP-701; RAP-164; RAP-310; RAP-163; RAP-103 | Phase 2 Clinical | Rapid Pharmaceuticals | Alzheimer Disease; Hepatitis B; Neuralgia; Ovarian Neoplasms; Prostatic Neoplasms; Psoriasis | 詳細 |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | 詳細 |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Amyotrophic Lateral Sclerosis; HIV Infections; Multiple Sclerosis | 詳細 | |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | 詳細 |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections | 詳細 |
| vMIP (Guangzhou Hongrun Biotech) | Phase 1 Clinical | Guangzhou Hongrun Biotechnology Co Ltd | Pneumonia | 詳細 | |
| LF-0376 | LF-0376 | Phase 1 Clinical | Wuxi Hillhouse biomedicine Technology Co Ltd | Colorectal Neoplasms; Liver Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Solid tumours | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | United States | HIV Infections | Viiv Healthcare Co | 2007-08-06 | Acquired Immunodeficiency Syndrome; Acute Lung Injury; AIDS Dementia Complex; Arthritis, Rheumatoid; Cardiovascular Diseases; Cognition Disorders; Coronavirus Disease 2019 (COVID-19); HIV Infections; Hypertriglyceridemia; Inflammation; Ischemic Stroke; Kidney Diseases; Primary Graft Dysfunction; Rejection of lung transplantation; Sarcoma, Kaposi; Stroke | 詳細 |